Belvedere Trading

Belvedere Trading’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Belvedere Trading’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Buy	+200	New	+$9.54K	﹤0.01%	935

Other funds holding GNOM

Sumitomo Mitsui Trust Group

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

SLT Holdings Scottsdale, Arizona $160M AUM 52.3% 1-Year Est. Return

Wealth Management Partners Tucson, Arizona $425M AUM 60.71% 1-Year Est. Return

Sightline Wealth Advisors Groton, Connecticut $273M AUM 18.08% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return

Gladstone Institutional Advisory Palm Beach Gardens, Florida $3.16B AUM 29.04% 1-Year Est. Return

J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Belvedere Trading's GNOM Position: Q2 2026 in Review

Belvedere Trading opened a new position in Global X Genomics & Biotechnology ETF (GNOM) in Q2 2026: 8,626 shares worth $490K. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings.

17 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Belvedere Trading held 8,626 shares of Global X Genomics & Biotechnology ETF worth $490K as of Q2 2026.
Global X Genomics & Biotechnology ETF was a new Belvedere Trading position in Q2 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Belvedere Trading's portfolio in Q2 2026, its #337 holding.
17 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.